|
Oct 7
|
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
|
|
Feb 2
|
Hansa Biopharma Year-end report January-December 2023
|
|
Dec 7
|
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
|
|
Dec 5
|
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
|
|
Jul 20
|
Hansa Biopharma half year report 2023
|
|
Jul 19
|
First patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitis
|